Dana Gelbaum

Dana Gelbaum serves as the Operations & Product Team Lead for AL102 at Immunome, Inc. since April 2024, while also being a member of 8400 - The Health Network since January 2019. Prior to this, Dana held various executive roles at Ayala Pharmaceuticals from December 2017 to April 2024, including General Manager & CBO, Chief Business Officer, and Senior Vice President Of Corporate Development, contributing to the development of targeted cancer therapies. Dana's extensive experience in the biopharmaceutical industry is further highlighted by leadership positions at Chiasma from 2009 to December 2019, including VP Global Marketing & Corporate Development. Additional roles include Chief Commercial Officer at Bioblast Pharma and Director of Business Development at Recoly NV, as well as positions at Johnson & Johnson Development Corporation and Ernst & Young. Dana Gelbaum holds an MSc in Molecular and Cellular Biology and an MBA in Finance from Tel Aviv University.